BR112013033363A2 - composição farmacêutica para tratamento de cicatrizes na pele, e método para tratar cicatrizes na pele usando a mesma - Google Patents

composição farmacêutica para tratamento de cicatrizes na pele, e método para tratar cicatrizes na pele usando a mesma

Info

Publication number
BR112013033363A2
BR112013033363A2 BR112013033363A BR112013033363A BR112013033363A2 BR 112013033363 A2 BR112013033363 A2 BR 112013033363A2 BR 112013033363 A BR112013033363 A BR 112013033363A BR 112013033363 A BR112013033363 A BR 112013033363A BR 112013033363 A2 BR112013033363 A2 BR 112013033363A2
Authority
BR
Brazil
Prior art keywords
treating skin
skin scars
pharmaceutical composition
dermis
scars
Prior art date
Application number
BR112013033363A
Other languages
English (en)
Inventor
Duck Kim Sang
Original Assignee
Duck Kim Sang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duck Kim Sang filed Critical Duck Kim Sang
Publication of BR112013033363A2 publication Critical patent/BR112013033363A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "composição farmacêutica para tratamento de cicatrizes na pele, e método para tratar cicatrizes na pele usando a mesma". a presente invenção refere-se a uma composição farmacêutica para o tratamento de cicatrizes na pele, que compreende uma mistura de toxina botulínica e ar. a mistura de toxina botulínica e de ar de acordo com a presente invenção, quando injetada na derme, pode temporariamente remover a elasticidade da derme e alisar a parte deprimida da cicatriz, e, portanto, permite uma elaborada resseção intradérmica e aumenta os efeitos terapêuticos dos lasers para o tratamento de laser corante pulsado ou laser fracionado. dessa maneira, as cicatrizes na pele podem ser melhoradas, de forma eficaz, através de uma operação única, sem afetar negativamente o cotidiano dos pacientes. 20099960v1
BR112013033363A 2011-06-27 2012-06-26 composição farmacêutica para tratamento de cicatrizes na pele, e método para tratar cicatrizes na pele usando a mesma BR112013033363A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161501624P 2011-06-27 2011-06-27
PCT/KR2012/005029 WO2013002531A2 (ko) 2011-06-27 2012-06-26 피부 흉터 치료용 약학적 조성물 및 이를 이용한 피부 흉터 치료 방법

Publications (1)

Publication Number Publication Date
BR112013033363A2 true BR112013033363A2 (pt) 2017-01-31

Family

ID=47424649

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033363A BR112013033363A2 (pt) 2011-06-27 2012-06-26 composição farmacêutica para tratamento de cicatrizes na pele, e método para tratar cicatrizes na pele usando a mesma

Country Status (8)

Country Link
US (2) US9050337B2 (pt)
EP (1) EP2724725B1 (pt)
KR (1) KR101455817B1 (pt)
CN (1) CN103501802B (pt)
AU (1) AU2012276512B2 (pt)
BR (1) BR112013033363A2 (pt)
ES (1) ES2604707T3 (pt)
WO (1) WO2013002531A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050337B2 (en) * 2011-06-27 2015-06-09 Sang Duck Kim Method for treating atrophic skin scars using a mixture of botulinum toxin and air
WO2016021985A1 (ko) * 2014-08-07 2016-02-11 김상덕 보툴리눔 독소와 공기의 혼합물을 포함하는 안면 윤곽 교정용 조성물 및 이를 이용한 안면 윤곽 교정 방법
KR101666838B1 (ko) 2015-05-13 2016-10-17 대구가톨릭대학교산학협력단 흉터 치료 시스템
CN110691579A (zh) * 2017-03-22 2020-01-14 邦蒂公司 用于治疗的肉毒杆菌神经毒素
US20190183987A1 (en) * 2017-12-18 2019-06-20 Bonti, Inc. Neurotoxins for use in minimizing scarring
KR20220169510A (ko) * 2021-06-18 2022-12-28 충북대학교 산학협력단 불멸화 줄기세포의 엑소좀 풍부 배양액 및 보툴리눔 독소를 포함하는 기능성 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
KR100491701B1 (ko) * 1997-12-19 2005-05-27 톰슨 라이센싱 소시에떼 아노님 원격 제어 장치 및 상기 원격 제어 장치를 프로그래밍하기 위한 방법
EP1128844B1 (en) * 1998-10-27 2006-01-04 Mayo Foundation For Medical Education And Research Botulinum toxins for enhancing wound healing
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
KR101224262B1 (ko) * 2004-03-22 2013-01-21 셀진 코포레이션 면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법
US20160095908A1 (en) * 2005-06-14 2016-04-07 Botulinum Toxin Research Associates, Inc. Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies
DK3144013T3 (en) * 2005-12-01 2019-03-04 Univ Massachusetts Lowell Botulinum nanoemulsions
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
EP3650017A1 (en) * 2008-06-26 2020-05-13 Anterios, Inc. Dermal delivery
CA2762959A1 (en) * 2009-05-29 2010-12-02 Symatese Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
US8454975B1 (en) * 2010-01-11 2013-06-04 Elizabeth VanderVeer Method for enhancing skin appearance
US20120189586A1 (en) * 2011-01-21 2012-07-26 Carl Randall Harrell Human Placental Derived Extracellular Matrix and Uses Therof
US9050337B2 (en) * 2011-06-27 2015-06-09 Sang Duck Kim Method for treating atrophic skin scars using a mixture of botulinum toxin and air

Also Published As

Publication number Publication date
US20140127186A1 (en) 2014-05-08
EP2724725A2 (en) 2014-04-30
WO2013002531A9 (ko) 2013-03-07
US9050337B2 (en) 2015-06-09
US20160106653A1 (en) 2016-04-21
KR101455817B1 (ko) 2014-11-04
CN103501802B (zh) 2016-03-16
EP2724725A4 (en) 2015-03-18
ES2604707T3 (es) 2017-03-08
WO2013002531A2 (ko) 2013-01-03
AU2012276512A1 (en) 2013-12-19
EP2724725B1 (en) 2016-09-07
WO2013002531A3 (ko) 2013-04-18
AU2012276512B2 (en) 2016-04-21
KR20130036758A (ko) 2013-04-12
CN103501802A (zh) 2014-01-08

Similar Documents

Publication Publication Date Title
BR112013033363A2 (pt) composição farmacêutica para tratamento de cicatrizes na pele, e método para tratar cicatrizes na pele usando a mesma
Heppt et al. Current strategies in the treatment of scars and keloids
Lanoue et al. Acne scarring: a review of cosmetic therapies
Stebbins et al. Novel method of minimally invasive removal of large lipoma after laser lipolysis with 980 nm diode laser
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
Casabona et al. Calcium hydroxylapatite combined with microneedling and ascorbic acid is effective for treating stretch marks
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
BR112015022588A2 (pt) composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo
CL2009002183A1 (es) Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica.
AR055038A1 (es) Metodo y compuesto para tratar enfermedades vasculares perifericas
BR112014029245A2 (pt) métodos para diminuir a proteína convertase subtilisina/quexina tipo 9 (pcsk9)
BR112015020196A2 (pt) uma composição tópica para clareamento e métodos de uso da mesma
BR112013030169A2 (pt) métodos de tratamento de esclerose múltipla e preservação e/ou aumento do teor de mielina
BRPI0417493B8 (pt) uso de uma toxina botulínica para tratamento de distúrbios da pele
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
BR112015006055A2 (pt) composições e métodos para o tratamento e prevenção de lesão tecidual e doença
BR112014009785A8 (pt) método para tratar ou reduzir efp
BR112015025901A2 (pt) composto, composição, kit, e, métodos para corregular ras/raf/mek/erk e pi3k/akt/pten/mtor, para tratar uma condição e uma doença e para monitorar a eficácia de um composto
BR112017020132A2 (pt) métodos para promover o crescimento capilar ou prevenir a perda de cabelo em um indivíduo e para preparar uma composição, e, composição
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
CY1120793T1 (el) Μεθοδοι θεραπευτικης αγωγης παθησεων που αφορουν μαλλια
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
AR094291A1 (es) Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un procedimiento para producirla

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2625 DE 27-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.